Financials data is unavailable for this security.
View more
Year on year Hikma Pharmaceuticals PLC had little change in net income (from 188.00m to 190.00m) despite revenues that grew 14.22% from 2.52bn to 2.88bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 49.74% to 51.06%.
| Gross margin | 47.40% |
|---|---|
| Net profit margin | 9.61% |
| Operating margin | 14.78% |
| Return on assets | 6.13% |
|---|---|
| Return on equity | 12.74% |
| Return on investment | 8.47% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Hikma Pharmaceuticals PLC fell by 65.00m. However, the company earned 608.00m from its operations for a Cash Flow Margin of 21.15%. In addition the company used 333.00m on investing activities and also paid 337.00m in financing cash flows.
| Cash flow per share | 1.72 |
|---|---|
| Price/Cash flow per share | 11.32 |
| Book value per share | 8.25 |
|---|---|
| Tangible book value per share | 4.30 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.66 |
|---|---|
| Quick ratio | 0.9775 |
| Total debt/total equity | 0.5582 |
|---|---|
| Total debt/total capital | 0.3568 |
More ▼
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 30.11% and 2.26%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 2.12% |
|---|---|
| Div growth rate (5 year) | 14.03% |
| Payout ratio (TTM) | 61.40% |
| EPS growth(5 years) | -6.02 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 93.85 |
More ▼
